|Venture Round, 1/2009 ||$3.11M|
|Partial Close, 8/2010 ||$2M|
|Partial Close, 10/2011 ||$2.89M|
|Venture Round, 3/2013 ||$8.27M|
|Venture Round, 7/2013 ||$9M|
PLx Pharma Inc., a pharmaceutical company, develops and commercializes non-steroidal anti-inflammatory drugs (NSAIDs) for prescription and over-the-counter markets in the United States. The company offers PL2200 Aspirin, a molecular complex of aspirin and phosphatidylcholine; and PL1100/1200 Ibuprofen, which are oral drug products containing a molecular complex of ibuprofen and phosphatidylcholine. It also provides other NSAID-PC products, which include PL4500 Indomethacin IV, a molecular complex of indomethacin and phosphatidylcholine that is developed in oral formulations and as an IV formulation for the treatment of PDA; and PL5100 Diclofenac, a molecular complex of diclofenac and phosphatidylcholine that is developed as an oral anti-inflammatory and analgesic drug. The company is based in Houston, Texas.